Companies › Grand Theravac Life Sciences (Nanjing)
1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TVAX-008 | – | Phase 2 | Chronic Hepatitis B Virus; HBV Infection | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07190742 | TVAX-008 | Phase 2 | Chronic Hepatitis B Virus | Infectious disease | Oct 2024 |
| NCT07179653 | TVAX-008 | Phase 2 | HBV Infection | Infectious disease | Dec 2026 |
No annotated target.
–
Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.